Patrick Lamy
Senior VP, Commercial Strategy at Akero Therapeutics, Inc. (AKRO) since January 2023
Patrick Lamy has filed 18 insider reports with the SEC since January 2023, as senior VP and commercial Strategy at Akero Therapeutics, Inc. (AKRO). Patrick Lamy made no open-market purchases or sales in the last 12 months. The latest filing, on December 9, 2025, reports sale back to the company at Akero Therapeutics, Inc. (AKRO).
- Filings
- 18
- Companies
- 1
- Bought on market
- None
- Sold on market
- $1.46M
Companies where Patrick Lamy is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Senior VP, Commercial Strategysince January 2023 | 0 | $1.46M | Dec 9, 2025 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Dec 9, 2025AKROOfficer Lamy Patrick returned 29,891 shares to the company, closing all direct ownership in the companyForm 4Sale back to the company
- Jul 1, 2025-$106KAKROSenior VP, Commercial Strategy Lamy Patrick sold $105,760 worth of shares (2,000 units at $52.88), decreasing direct ownership by 6% to 29,891 unitsForm 4Open-market sale10b5-1 plan
- Jun 30, 2025AKROSenior VP, Commercial Strategy Lamy Patrick was granted 193 shares, increasing direct ownership by 0.61% to 31,891 unitsForm 4Grant or award
- Jun 20, 2025-$47.8KAKROSenior VP, Commercial Strategy Lamy Patrick sold $47,766 worth of shares (875 units at $54.59), decreasing direct ownership by 3% to 31,698 unitsForm 4Open-market sale
- Jun 16, 2025-$108KAKROSenior VP, Commercial Strategy Lamy Patrick exercised 2,000 shares at a strike of $19.87 and sold $108,272 worth of shares (2,000 units at $54.14)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jun 10, 2025-$49.6KAKROSenior VP, Commercial Strategy Lamy Patrick sold $49,625 worth of shares (919 units at $54.00), decreasing direct ownership by 3% to 32,573 unitsForm 4Open-market sale
- Jun 2, 2025-$201KAKROSenior VP, Commercial Strategy Lamy Patrick exercised 4,000 shares at a strike of $19.87 and sold $201,258 worth of shares (4,000 units at $50.31)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- May 22, 2025-$200KAKROSenior VP, Commercial Strategy Lamy Patrick exercised 4,000 shares at a strike of $44.37 and sold $200,000 worth of shares (4,000 units at $50.00)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- May 7, 2025-$340KAKROSenior VP, Commercial Strategy Lamy Patrick exercised 8,000 shares at a strike of $19.87 and sold $339,950 worth of shares (8,000 units at $42.49)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 3, 2025-$48.1KAKROSenior VP, Commercial Strategy Lamy Patrick exercised 1,000 shares at a strike of $19.87 and sold $48,090 worth of shares (1,000 units at $48.09)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 27, 2025-$285KAKROSenior VP, Commercial Strategy Lamy Patrick was granted 234 shares, exercised 4,000 shares at a strike of $19.87 and sold $285,150 worth of shares (5,000 units at $57.03), decreasing direct ownership by 2% to 33,492 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Dec 16, 2024-$29.1KAKROSenior VP, Commercial Strategy Lamy Patrick was granted 17,400 shares and sold $29,130 worth of shares (1,000 units at $29.13), increasing direct ownership by 92% to 34,258 unitsForm 4Grant or awardOpen-market sale10b5-1 plan
- Dec 10, 2024-$28.5KAKROSenior VP, Commercial Strategy Lamy Patrick sold $28,481 worth of shares (925 units at $30.79), decreasing direct ownership by 5% to 17,858 unitsForm 4Open-market sale
- Jun 28, 2024AKROSenior VP, Commercial Strategy Lamy Patrick was granted 221 shares, increasing direct ownership by 1% to 18,783 unitsForm 4Grant or award
- Jun 11, 2024-$12.9KAKROSenior VP, Commercial Strategy Lamy Patrick sold $12,883 worth of shares (569 units at $22.64), decreasing direct ownership by 3% to 18,562 unitsForm 4Open-market sale
- Dec 8, 2023AKROLamy Patrick was granted 18,570 sharesForm 4Grant or award
- Jan 10, 2023AKROSEC Form 4 filed by Lamy PatrickForm 4Grant or award
- Jan 10, 2023AKROPatrick Lamy became an insiderForm 3New insider
Compare Patrick Lamy with
- Patrick Lamy vs Tomas J. Heyman1 shared
- Patrick Lamy vs Yuan Xu1 shared
- Patrick Lamy vs Andrew Cheng1 shared
- Patrick Lamy vs Seth Loring Harrison1 shared
- Patrick Lamy vs G. Walmsley Graham1 shared
- Patrick Lamy vs Chou Judy1 shared
Other insiders at the same companies
- Tomas J. HeymanAKRO
- Yuan XuAKRO
- Andrew ChengAKRO
- Seth Loring HarrisonAKRO
- G. Walmsley GrahamAKRO
- Chou JudyAKRO
- Timothy RolphAKRO
- Mark T IwickiAKRO
- Scott A. GangloffAKRO
- William Richard WhiteAKRO
- Catriona YaleAKRO
- Jane HendersonAKRO
- Jonathan YoungAKRO
Questions about Patrick Lamy
- What is Patrick Lamy's role at Akero Therapeutics, Inc.?
- Patrick Lamy reports to the SEC as senior VP and commercial Strategy at Akero Therapeutics, Inc. (AKRO), according to the latest filing on December 9, 2025.
- Has Patrick Lamy bought or sold stock recently?
- The most recent open-market sale was on July 1, 2025: sold 2,000 shares of Akero Therapeutics, Inc. (AKRO) for $106K at an average of $52.88.
- How do I get alerts when Patrick Lamy files?
- Follow Patrick Lamy on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Patrick Lamy (SEC CIK 0001961273). Totals count each trade once, skipping amendments whose original is on file, from Jan 12, 2023 on. View on SEC EDGAR